Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision
Retinitis Pigmentosa
About this trial
This is an interventional supportive care trial for Retinitis Pigmentosa focused on measuring Retinitis pigmentosa,, stemcell, Wharton jelly, umbilical cord, mesenchymal stemcell, electromagnetic stimulation, iontophoresis, Magnovision.
Eligibility Criteria
Inclusion Criteria: RP patients of any genotype and phenotype; BCVA better than 35 letters; Any degree and kind of visual field loss; Over 18 years old. Exclusion Criteria: The presence of glaucoma, Dense cataracts Dense vitreus opacities Autoimmune retinopathy-like clinical picture Any degree of smoking Presence of systemic neurological disease with seizure Presence of a cardiac pacemaker.
Sites / Locations
- BioRetina
- Ankara University Biotechnology Institute
- Umut Arslan
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
No Intervention
Only WJ-MSCs
Only rEMS
WJ-MSCs and rEMS combination
The natural course
Consisted of 34 eyes of 32 RP patients treated with only WJ-MSCs, and it was applied only once following necessary preparations. After the inoculation of stem cells, the patients were followed up regularly on the 10th day, 3rd month, and every 6 months after that until 36 th months. For ethical reasons, the worse eye was selected to inject the stem cells instead of both eyes.
Consisted of 32 eyes of 16 RP patients treated with only rEMS. rEMS was applied with a custom-designed helmet once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
Consisted of 32 eyes of 16 RP patients treated with the WJ-MSCs and rEMS combination. WJ-MSCs were applied first into the deep subtenon space of both eyes after necessary preparations. rEMS application was started 10 days after the WJ-MSC application with a custom-designed helmet for 30 min. WJ-MSCs were inoculated only once, and rEMS was applied regularly once a week for 30 min for 36 months. Both eyes are stimulated at the same time with the specially designed system for ophthalmologic use (MagnoVisionTM).
The natural course (control) group consisted of 32 eyes of 16 RP patients who received no treatment and were regularly followed until the 36th month. This group comprised patients who did not accept any treatment and/or were in good condition at baseline.